Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 43

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q70EL4

UPID:

UBP43_HUMAN

Alternative names:

Deubiquitinating enzyme 43; Ubiquitin thioesterase 43; Ubiquitin-specific-processing protease 43

Alternative UPACC:

Q70EL4; A6NDT9; B7ZLT9; B7ZVX5; Q8N2C5; Q96DQ6

Background:

Ubiquitin carboxyl-terminal hydrolase 43, also known as Deubiquitinating enzyme 43, plays a crucial role in cellular processes by recognizing and hydrolyzing the peptide bond at the C-terminal Gly of ubiquitin. This enzyme is pivotal in the processing of poly-ubiquitin precursors and ubiquitinated proteins, suggesting its integral role in protein degradation pathways.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase 43 could open doors to potential therapeutic strategies. Its involvement in ubiquitin-mediated processes positions it as a key target for drug discovery, aiming to modulate protein degradation pathways for therapeutic benefits.